Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 392

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 392
---
chst KG(b) |       31.2 |  102 |   90 |   97 |
| MSP Vaccine Company(c)            |       50.0 |   81 |   96 |  104 |
| Other investments                 |          — |   51 |   76 |   84 |
| Total                             |            |  316 |  424 |  677 |

(a) The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (€ 2.88 as of December 31, 2024, and € 5.73

as of December 31, 2023) .

(b) Joint venture.

(c) Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV .

The table below shows Sanofi’s overall share of (i) profit or loss and (ii) other comprehensive income from investments accounted

for using the equity method, showing the split between associates and joint ventures in accordance with IFRS 12 (the amounts for

each individual associate or joint venture are not material):

|                                                                                          |           2024 |            |           2023 |            |           2022 |            |
| (€ million)                                                                              | Joint ventures | Associates | Joint ventures | Associates | Joint ventures | Associates |
| Share of profit/(loss) from investmentsaccounted for using the equity method(a)          |            134 |        -74 |            101 |       -237 |             73 |        -18 |
| Share of other comprehensive income frominvestments accounted for using the equitymethod |              3 |         -5 |             -7 |          7 |             -3 |         -1 |
| Total                                                                                    |            137 |        -79 |             94 |       -230 |             70 |        -19 |

(a) The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (€ 2.88 as of December 31, 2024, and € 5.73

as of December 31, 2023).

The financial statements include arm’s length transactions between Sanofi and some equity-accounted investments that are

classified as related parties. The principal transactions and balances with related parties are summarized below:

| (€ million)                                                   | 2024 | 2023 | 2022(a) |
| Sales(d)                                                      |  103 |  157 |